
|Articles|July 26, 2002
Cancer vaccine gets orphan drug status
Antigenics Inc. reports the U.S. Food and Drug Administration grantedthe company's personalized cancer vaccine (Oncophage) orphan drug statusfor the treatment of metastatic melanoma. This offers the company potentialmarket exclusivity for seven years from FDA marketing approval.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
3
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















